KORLYM

Peak

mifepristone

NDAORALTABLET
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17

Mechanism of Action

Progestational Hormone Receptor Antagonists

Pharmacologic Class:

Progestin Antagonist

Clinical Trials (5)

NCT06099769Phase 2Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Started Oct 2023
201 enrolled
Metastatic Breast Cancer
NCT05772169Phase 4Completed

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

Started Mar 2023
1,113 enrolled
HypercortisolismDiabetes Mellitus, Type 2
NCT04588688Phase 2Terminated

Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

Started May 2021
3 enrolled
Central Adrenal InsufficiencyMifepristone
NCT03379363N/ATerminated

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

Started Sep 2017
2 enrolled
HypercortisolismCushing Syndrome
NCT03258372Phase 1Completed

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Started Aug 2017
48 enrolled
Healthy

Loss of Exclusivity

LOE Date
Aug 22, 2038
151 months away
Patent Expiry
Aug 22, 2038

Patent Records (5)

Patent #ExpiryTypeUse Code
8921348
Aug 27, 2028
U-1643
10842801
Nov 15, 2032
U-1643
10500216
Mar 5, 2033
U-1643
9943526
Apr 20, 2036
U-1643
10166242
Apr 20, 2036
U-1643